v3.26.1
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Research and development revenue $ 3,991 $ 6,707
Cost of revenue (1,964) (3,539)
Gross profit 2,027 3,168
Operating costs and expenses:    
General and administrative 3,998 4,064
Total operating costs and expenses 3,998 4,064
Operating loss (1,971) (896)
Other income (expense):    
Net interest (expense) income (258) (20)
Financing related costs (7) (581)
Amortization of debt discount (179)
Change in fair value of warrant liability (1,002) 4,253
Change in fair value of notes payable   (220)
Foreign exchange transaction loss, net (5) (8)
Total other income (expense), net (1,451) 3,864
Income (loss) before income taxes (3,422) 2,968
Income tax provision 10 (71)
Net income (loss) $ (3,412) $ 2,897
Net income (loss) per share of common stock    
Basic (in Dollars per share) $ (0.11) $ 0.13
Diluted (in Dollars per share) $ (0.11) $ 0.11
Weighted-average common shares outstanding    
Basic (in Shares) 31,756,649 22,986,350
Diluted (in Shares) 31,756,649 24,030,518
Other comprehensive income (loss):    
Foreign currency translation adjustments $ (10) $ 17
Total comprehensive income (loss) $ (3,422) $ 2,914